ClinicalTrials.Veeva

Menu

Defeat Rare Disease in Asia and Pacific (APAC) DRDA - Haemophilia

Novo Nordisk logo

Novo Nordisk

Status

Invitation-only

Conditions

Haemophilia

Treatments

Other: No treatment given

Study type

Observational

Funder types

Industry

Identifiers

NCT07163260
U1111-1303-7372 (Other Identifier)
DAS-8107

Details and patient eligibility

About

This study will help to better understand the course of disease in people with haemophilia (A or B [with or without inhibitors]) and the haemophilia care scenario in the selected countries and the experience so far in dealing with the condition. This is a survey-based study; hence no medications or other treatments will be provided to participants as a part of this study.

Enrollment

244 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

For Experienced/Senior Treating Physicians

  • Experienced/senior haematologist treating haemophilia (adult or paediatric) or physician treating patients with haemophilia. (PWH), with greater than 5 years of experience.

  • Able to communicate in English or country specific language.

  • Agree/sign informed consent before data collection. For Patients Organisations

  • Patient organisation supporting haemophilia.

  • Expert having greater than 3 years of work experience with the patient organisation.

  • Expert level understanding of haemophilia landscape and care pathway in the relevant country.

  • Able to communicate in English or country specific language.

  • Agree/sign informed consent before data collection. For Patients/Caregivers

    1. Patients of all age groups, diagnosed with haemophilia A or haemophilia B (with or without inhibitors) for greater than 2 years.

    2. For patients less than 18 years of age (*less than 19 years for South Korea), their caregivers aged greater than or equal to 18 years (*greater than or equal to19 years for South Korea) should sign the informed consent.

      *For South Korea, the adult age is 19 years.

    3. Able to communicate in English or country specific language.

    4. Agree/sign informed consent before data collection.

      Exclusion Criteria:

  • There is no explicit exclusion criterion in this study, thus any participants group who answers "no" to any of the inclusion criteria will be excluded from the study.

Trial design

244 participants in 3 patient groups

Experienced/Senior Treating Physicians
Description:
This group includes haematologists, paediatric haematologist and physicians treating patients with haemophilia (PWH)
Treatment:
Other: No treatment given
Patients Organisations
Description:
This group includes the organisations working closely to support patient with haemophillia (PWH) at a national/regional level
Treatment:
Other: No treatment given
Patients/Caregivers
Description:
This group includes patients with haemophilia and caregivers managing patients with haemophilia
Treatment:
Other: No treatment given

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems